Golden Ten Data, December 27th, Haier Biomedical announced that the company is planning to absorb and merge Shanghai Laisi through Haier Biomedical by issuing A-shares to all shareholders of Shanghai Laisi and raising funds through the issuance of A-shares. Due to the planning of major asset restructuring, the company's securities have been suspended from trading since the opening of the market on December 23, 2024, and the suspension is expected to last no more than 10 trading days. As of the date of this announcement, the company and relevant parties are actively advancing the relevant work of this transaction.
Ver originales
Esta página puede contener contenido de terceros, que se proporciona únicamente con fines informativos (sin garantías ni declaraciones) y no debe considerarse como un respaldo por parte de Gate a las opiniones expresadas ni como asesoramiento financiero o profesional. Consulte el Descargo de responsabilidad para obtener más detalles.
Haier Bio: Planificación de importantes operaciones de reestructuración de activos
Golden Ten Data, December 27th, Haier Biomedical announced that the company is planning to absorb and merge Shanghai Laisi through Haier Biomedical by issuing A-shares to all shareholders of Shanghai Laisi and raising funds through the issuance of A-shares. Due to the planning of major asset restructuring, the company's securities have been suspended from trading since the opening of the market on December 23, 2024, and the suspension is expected to last no more than 10 trading days. As of the date of this announcement, the company and relevant parties are actively advancing the relevant work of this transaction.